ImmunityBio Inc (NASDAQ:IBRX)’s traded shares stood at 9.67 million during the last session, with the company’s beta value hitting 0.07. At the close of trading, the stock’s price was $2.65, to imply a decrease of -8.62% or -$0.25 in intraday trading. The IBRX share’s 52-week high remains $7.63, putting it -187.92% down since that peak but still an impressive 30.94% since price per share fell to its 52-week low of $1.83. The company has a valuation of $2.34B, with an average of 11.22 million shares in intraday trading volume over the past 10 days and average of 7.74 million shares over the past 3 months.
Analysts have given a consensus recommendation of Sell for ImmunityBio Inc (IBRX), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 1 analyst(s) give IBRX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 0 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.1.
ImmunityBio Inc (NASDAQ:IBRX) trade information
After registering a -8.62% downside in the last session, ImmunityBio Inc (IBRX) has traded red over the past five days. The 5-day price performance for the stock is 6.43%, and -1.49% over 30 days. With these gigs, the year-to-date price performance is 3.52%. Short interest in ImmunityBio Inc (NASDAQ:IBRX) saw shorts transact 68.76 million shares and set a 10.19 days time to cover.
The extremes give us $6 and $6 for target low and target high price respectively. As such, IBRX has been trading -126.42% off suggested target high and -126.42% from its likely low.
ImmunityBio Inc (IBRX) estimates and forecasts
The rating firms project that company’s revenue will grow 573.82% compared to the previous financial year.
Revenue forecast for the current quarter as set by 4 analysts is 21.95M. Meanwhile, for the current quarter, a total of 4 analyst(s) estimate revenue growth to 27.85M.Earnings reports from the last fiscal year show that sales brought in 1.05M and 6.11M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 1,996.47% before jumping 356.07% in the following quarter.
IBRX Dividends
ImmunityBio Inc has its next earnings report out on 2025-May-11. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
ImmunityBio Inc (NASDAQ:IBRX)’s Major holders
ImmunityBio Inc insiders hold 74.11% of total outstanding shares, with institutional holders owning 9.23% of the shares at 35.66% float percentage. In total, 9.23% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 13.83 million shares (or 2.0135% of shares), all amounting to roughly $87.42 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 11.42 million shares, or about 1.6629% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $72.19 million.
We also have VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund as the top two Mutual Funds with the largest holdings of the ImmunityBio Inc (IBRX) shares. Going by data provided on Dec 31, 2024 , VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund holds roughly 5.73 shares. This is just over 0.65% of the total shares, with a market valuation of $15.19 million. Data from the same date shows that the other fund manager holds a little less at 4.65, or 0.53% of the shares, all valued at about 12.32 million.
